The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy

Prostate-specific membrane antigen (PSMA) is a type 2 integral membrane glycoprotein that serves as an attractive target for cancer immunotherapy by virtue of its abundant and restricted expression on the surface of prostate carcinomas and the neovasculature of most other solid tumors. However, relatively little is known about the molecular structure of this target. Here, we report that PSMA is expressed on tumor cells as a noncovalent homodimer. A truncated PSMA protein, lacking transmembrane and cytoplasmic domains, also formed homodimers, indicating that the extracellular domain is sufficient for dimerization. PSMA dimers but not monomers displayed a native conformation and possessed high-level carboxypeptidase activity. A unique dimer-specific epitope was identified by using one of a panel of novel mAbs. When used to immunize animals, dimer but not monomer elicited antibodies that efficiently recognized PSMA-expressing tumor cells. These findings on PSMA structure and biology may have important implications for active and passive immunotherapy of prostate and other cancers.

[1]  Min Lu,et al.  Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein , 2002, Journal of Virology.

[2]  George L. Wright,et al.  Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.

[3]  J. Mendelsohn.  Targeting the epidermal growth factor receptor for cancer therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Bittner,et al.  Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. , 2001, Cancer research.

[5]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[6]  Lesley Seymour,et al.  Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. , 2003, The Lancet. Oncology.

[7]  V. Reuter,et al.  Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. , 2001, Urology.

[8]  B. Suffoletto,et al.  Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  Jeffrey A. Magee,et al.  Expression profiling reveals hepsin overexpression in prostate cancer. , 2001, Cancer research.

[11]  J. Neefs,et al.  Isolation and Expression of Novel Human Glutamate Carboxypeptidases with N-Acetylated α-Linked Acidic Dipeptidase and Dipeptidyl Peptidase IV Activity* , 1999, The Journal of Biological Chemistry.

[12]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[13]  M. Morrow,et al.  Chemoprevention of breast cancer: a model for change. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Tortella,et al.  Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury , 1999, Nature Medicine.

[15]  B. Slusher,et al.  Characterization of the enzymatic activity of PSM: Comparison with brain NAALADase , 1999, The Prostate.

[16]  J. Coyle,et al.  Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. , 1999, Molecular pharmacology.

[17]  H. Schägger,et al.  Analysis of molecular masses and oligomeric states of protein complexes by blue native electrophoresis and isolation of membrane protein complexes by two-dimensional native electrophoresis. , 1994, Analytical biochemistry.

[18]  M. Sliwkowski,et al.  Perspectives on Anti-HER Monoclonal Antibodies , 2002, Oncology.

[19]  N. Gironès,et al.  Intermolecular disulfide bonds are not required for the expression of the dimeric state and functional activity of the transferrin receptor. , 1989, The EMBO journal.

[20]  J. Coyle,et al.  Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[22]  N. Rawlings,et al.  Structure of membrane glutamate carboxypeptidase. , 1997, Biochimica et biophysica acta.

[23]  Dennis R. Burton,et al.  Why do we not have an HIV vaccine and how can we make one? , 1998, Nature Medicine.

[24]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[25]  L. Freeman,et al.  The role of (111)In Capromab Pendetide (Prosta-ScintR) immunoscintigraphy in the management of prostate cancer. , 2002, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[26]  V. Reuter,et al.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  W. Fair,et al.  Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. , 1993, Cancer research.

[28]  J. Konvalinka,et al.  Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II , 2002, Journal of neurochemistry.

[29]  J. Welsh,et al.  Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. , 2001, Cancer research.

[30]  B Chevrier,et al.  The structure of the Aeromonas proteolytica aminopeptidase complexed with a hydroxamate inhibitor. Involvement in catalysis of Glu151 and two zinc ions of the co-catalytic unit. , 1996, European journal of biochemistry.

[31]  H. Schägger,et al.  Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. , 1991, Analytical biochemistry.

[32]  S. Harrison,et al.  Crystal structure of the ectodomain of human transferrin receptor. , 1999, Science.

[33]  W. Fair,et al.  Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. , 1995, Cancer research.

[34]  M. Sadelain,et al.  A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? , 2001, Critical reviews in immunology.

[35]  N. Bander,et al.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.

[36]  Larry L. Green,et al.  Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice , 1997, Nature Genetics.